




CANONIC

Bringing precision
to medical cannabis

Safe harbor

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

About us

- Canonic is a fully owned subsidiary of Evogene Ltd* targeted to develop medical grade cannabis through a revolutionary approach utilizing disruptive genomic, big data and artificial intelligence technological platform
- Focused on improving yield and metabolite stability, and cannabis varieties for the main medical indications: PTSD, severe chronic pain and cancer
- Harnessing more than 10 years of Evogene's experience and reputation in plant genomics, including collaborations with international ag companies - Bayer, Corteva, Monsanto, Syngenta, and others
- Exclusive access to Evogene's CPB platform technology, IP and infrastructure for its cannabis R&D program including regulatory approvals for the establishment of a cannabis research facility

*Evogene Ltd. – Publicly traded in TASE and NASDAQ (EVGN); Cash balance of > \$50 Million (31/12/2018)

Agenda

Mission, Market & Challenges

Solution & Technology

Target Products & Business Plan

Assets & Capabilities


Summary

To develop and bring to market
medical grade cannabis
through a revolutionary genomic approach



The cannabis market

A fast growing market



Source: New frontier data (US only)

Vast medical applications



Source: Leafly Holdings

KEY CHALLENGES



METABOLITE YIELD


Low yields burden growers and patients with higher product and manufacturing costs.

\$980
per pound
Production cost

\$1,869
Annual average
expenditure of
medical cannabis user


VARIETY STABILITY

Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.



MEDICAL TAILORED PRODUCTS

Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.



Agenda

Mission, Market & Challenges

Solution & Technology

Target Products & Business Plan


Assets & Capabilities

Summary


Our solution

Using computational power (AI, Big Data) to decode the cannabis genome and overcome market challenges

Current cannabis genetic mapping




Canonic: seeing the bigger picture



■ Essential genes ■ CBD gene ■ THC genes ■ Proprietary high yield genes

Disruptive technology- the CPB Platform

Evogene's Computational Predictive Biology (CPB) platform



Collaborations over the years with:



MONSANTO

syngenta

CORTEVA[™]
agriscience

BASF
We create chemistry

And more...

CANONIC

Agenda

Mission, Market & Challenges

Solution & Technology

Target Products & Business Plan

Assets & Capabilities

Summary

Target products



MetaYield⁺

Increased **METABOLITE YIELD**



Unican⁺

Verified **VARIETY STABILITY**



Precise⁺

Tailored **METABOLITE PROFILES**



Precise⁺ Chronic pain




Precise⁺ PTSD



Precise⁺ Cancer care

Innovative products to
address key market
needs



+ For illustration purposes

Business plan

Canonic will develop elite cannabis varieties for commercialization of medical products directly or via partnerships

CANONIC

Potential partnerships

Varieties dev.

Unique
varieties

Seed production

Seeds

Cannabis growth

Flowers

Formulation

Clinical
validation &
regulation

Distribution

Milestones roadmap

2019

- Establishment of R&D growing facility
- Complete two cannabis growth cycles
- Establish agronomic protocols
- Build cannabis core collection
- Establish initial cannabis database



2020

- First product trait demonstrated
- Complete three cannabis growth cycles
- Complete establishment of proprietary cannabis database
- Expand core collection of cannabis varieties



2021

- Finalize development of first improved variety
- Pre-commercial stage
- Seed increase to allow production
- Finalize formulation process



Agenda

Mission, Market & Challenges


Solution & Technology

Target Products & Business Plan


Assets & Capabilities

Summary

Innovative technology implementation



Proprietary advantage



*In greenhouse

KEY CHALLENGES



METABOLITE YIELD


Low yields burden growers and patients with higher product and manufacturing costs.

\$980
per pound
Production cost

\$1,869
Annual average
expenditure of
medical cannabis user


VARIETY STABILITY

Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.



MEDICAL TAILORED PRODUCTS

Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.



Assets & capabilities from Evogene:

Metabolites yield example

**Cannabis metabolites are produced in small hairs (trichomes).
We have proprietary IP for trichome enhancement**

Trichomes in cannabis



**Cannabis yield is determined by its
trichome population**

Evogene has discovered genes for the
improvement of **trichomes density
and/or length**

>15 genes exhibited a **significant
impact on trichome traits** in model
plant systems

Most of the genes are under **granted
patents**

**Improved trichomes in
tomato**



KEY CHALLENGES



METABOLITE YIELD


Low yields burden growers and patients with higher product and manufacturing costs.

\$980
per pound
Production cost

\$1,869
Annual average
expenditure of
medical cannabis user


VARIETY STABILITY

Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.



MEDICAL TAILORED PRODUCTS


Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.



Variety stability example

THE CHALLENGE

Current medical products are unreliable due to large fluctuations in active compounds levels




- Underground breeding
- High genome heterogeneity
- Confusing varieties nomenclature



THE SOLUTION

Development of stable cannabis varieties using advanced plant genomics capabilities



Smart selection process – identify genotypes using computational tools

- Advanced breeding - superior performance
- Homogenous genome
- Hybrid seeds


Conducted by Evogene subsidiary on Castor

Assets & capabilities from Evogene:

Variety stability example

THE CHALLENGE

Current medical products are unreliable due to large fluctuations in active compounds levels




CANONIC



THE SOLUTION

Development of stable cannabis varieties using advanced plant genomics capabilities



Conducted by Evogene subsidiary on Castor

CANONIC

KEY CHALLENGES



METABOLITE YIELD


Low yields burden growers and patients with higher product and manufacturing costs.

\$980
per pound
Production cost

\$1,869
Annual average
expenditure of
medical cannabis user


VARIETY STABILITY

Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.



MEDICAL TAILORED PRODUCTS


Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.



Assets & capabilities from Evogene:

Metabolite profiles example

CANONIC



Connecting specific metabolites to clinical indications for precision medical cannabis products

CANONIC

The team

Chairman



Ofer Haviv

Evogene CEO and President

Management



Dr. Inbal Dangoor
R&D

Biotech Trait Manager, Ag seeds division
Evogene

PhD Plant science



Dr. Arnon Heyman
CEO

VP and GM Ag seeds division Evogene,
CTO BondX technologies

PhD Biotechnology, MBA



Ofir Hazut
Strategy & BD

Director of business development Evogene
MEway Pharma,
DiagnosticAid Medical,
PeriTech Pharma

MSc Neuroscience, MBA

Agenda

Mission, Market and Challenges

Solution & Technology


Target Products & Business Plan

Assets & Capabilities

Summary

Summary

- Canonic's mission is to develop and bring to market medical grade cannabis through a revolutionary genomic approach
- The cannabis market is growing at a rapid pace, while the main market challenges are – yield, stability and tailored products for specific indications
- Harnessing more than 10 years of Evogene's experience and reputation in plant genomics, including collaborations with international ag companies - Bayer, Corteva, Monsanto, Syngenta, and others
- Exclusive access to Evogene's CPB platform technology, IP and infrastructure for its cannabis R&D program including regulatory approvals for the establishment of a cannabis research facility



CANONIC

Bringing precision
to medical cannabis